Home・Aktien・MacroGenics Inc

MacroGenics Inc

Geschlossen

BrancheGesundheitswesen

4.04 -1.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.03

Max

4.09

Schlüsselkennzahlen
By Trading Economics
Einkommen	56M 20M
Verkäufe	12M 33M
EPS	-0.27
Gewinnspanne	59.439
Angestellte	293
EBITDA	16M -14M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+70.73% upside

Dividenden
By Acuity
Nächstes Ergebnis	10. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-702K 259M
Vorheriger Eröffnungskurs	5.26
Vorheriger Schlusskurs	4.04

Nachrichtenstimmung

By Acuity

29%

71%

84 / 340 Ranking in Healthcare

MacroGenics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

MacroGenics Inc Prognose

Kursziel

By TipRanks

70.73% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD 70.73%

Hoch 11 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für MacroGenics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für MacroGenics Inc – Dist abgegeben haben.

Stimmung

By Acuity

84 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.